These findings suggest that afatinib effectively inhibits HER2-overexpressed CRC cell growth and the afatinib/micelles significantly increase the accumulation of afatinib in tumor tissues and improve the therapeutic efficacy of afatinib in HER2-overexpressed CRC tumors. Here, ERBB2 is linked to colorectal carcinoma.